Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 3/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL8470122 | 1.00 | DYRK1A (0.49) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL447498 | 0.94 | DYRK1A (0.43) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL1730016 | 0.91 | DYRK1A (0.42) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL13516878 | 0.91 | KDM4E (0.44) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL8471715 | 0.91 | PNP (0.51) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL4007020 | 0.87 | ATAD2 (0.41) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| 2,6-Diaminopurine SCHEMBL23292803 | 0.86 | DYRK1A (0.38) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL5259 | 0.86 | ALDH1A1 (0.61) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL4658042 | 0.86 | ALDH1A1 (0.61) | DYRK1AKDM4EALDH1A1LMNAGLA | |
| Guanine SCHEMBL865492 | 0.85 | ALDH1A1 (0.59) | DYRK1AKDM4EALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 562 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268994-A1 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | TRANSLATE BIO, INC. (US) | 2025-08-28 | — | — | US | claimed |
| US-12203083-B2 | Programmable epigenetic control of gene expression in plants | DECIBEL BIO, INC (US) | 2025-01-21 | — | — | US | claimed |
| US-12195724-B2 | Methods of producing T cell populations enriched for stable regulatory T-cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-01-14 | — | — | US | claimed |
| US-20240342269-A1 | OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SARS-COV-2 ANTIGENS | TRANSLATE BIO, INC. | 2024-10-17 | — | — | US | claimed |
| CN-112201307-B | Transcript annotation method and method for screening long non-coding RNA and endogenous retrovirus-derived long non-coding RNA | 温州医科大学 | 2024-09-17 | — | — | CN | claimed |
| CN-117736984-A | Regulatory B cell producing interleukin-37 and preparation method and application thereof | 深圳大学 | 2024-03-22 | — | — | CN | claimed |
| EP-4313115-A1 | OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING THE EXTRACELLULAR DOMAIN OF HUMAN ACE2 PROTEIN OR A PORTION THEREOF | Translate Bio, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| US-11802303-B2 | Methods for multiplexed cell isolation using DNA gates | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-10-31 | — | — | US | claimed |
| US-20230304028-A1 | PROGRAMMABLE EPIGENETIC CONTROL OF GENE EXPRESSION IN PLANTS | Sound Agriculture Company (US) | 2023-09-28 | — | — | US | claimed |
| CN-116710557-A | Optimized nucleotide sequence for coding SARS-COV-2 antigen | 翻译生物公司 | 2023-09-05 | — | — | CN | claimed |
| US-9382308-B2 | CD133 epitopes | CEDARS-SINAI MEDICAL CENTER (US) | 2016-07-05 | — | — | US | claimed |
| US-9068020-B2 | CD133 epitopes | CEDARS-SINAI MEDICAL CENTER (US) | 2015-06-30 | — | — | US | claimed |
| US-20150118183-A1 | NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION | CUREVAC GMBH (DE) | 2015-04-30 | — | — | US | claimed |
| EP-2809354-A1 | NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION | Curevac GmbH (DE) | 2014-12-10 | — | — | EP | claimed |
| US-20130236496-A1 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE | UNIVERSITE DE LAVAL (CA) | 2013-09-12 | — | — | US | claimed |
| WO-2013113502-A1 | NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION | CUREVAC GMBH (DE) | 2013-08-08 | — | — | WO | claimed |
| US-20130183378-A1 | CD133 Epitopes | CEDARS-SINAI MEDICAL CENTER (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012000082-A1 | USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-L-LIKE RECEPTOR LIGAND OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE | UNIVERSITé LAVAL (CA) | 2012-01-05 | — | — | WO | claimed |
| CN-1554359-A | Process for preparing cytosine suanine dinuleotide sequence molecule immunopotentiator | 广东省农业科学院农业生物技术研究所 | 2004-12-15 | — | — | CN | claimed |
| US-5077196-A | Arabinonucleic acid segment-containing probes for DNA/RNA assays | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-12-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240342269-A1 | OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING SARS-COV-2 ANTIGENS | ACE2, TMPRSS2, SARS1 | DYRK1A 4708/4885KDM4E 4716/4885ALDH1A1 4808/4885 |
| US-20250268994-A1 | Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof | ACE2, LNPEP, ACE | DYRK1A 4816/4885KDM4E 4474/4885ALDH1A1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.